In this prospective survey of referring physicians, we investigated whether and how 68Ga-labeled prostate-specific membrane antigen 11 (68Ga-PSMA-11) PET/CT affects the implemented management of prostate cancer patients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-202 ng/mL). Referring physicians completed one questionnaire before the scan to indicate the treatment plan without 68Ga-PSMA-11 PET/CT information (Q1; n = 101), one immediately after the scan to denote intended management changes (Q2; n = 101), and one 3-6 mo later to document the final implemented management (Q3; n = 56). The implemented management was also obtained via electronic chart review or patient contact (n = 45). Results: A complete documented management strategy (Q1 + Q2 + implemented management) was available for 101 of 161 patients (63%). Seventy-six of these (75%) had a positive 68Ga-PSMA-11 PET/CT result. The implemented management differed from the prescan intended management (Q1) in 54 of 101 patients (53%). The postscan intended management (Q2) differed from the prescan intended management (Q1) in 62 of 101 patients (61%); however, these intended changes were not implemented in 29 of 62 patients (47%). Pelvic nodal and extrapelvic metastatic disease on 68Ga-PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) was significantly associated with implemented management changes (P = 0.001 and 0.05). Conclusion: Information from 68Ga-PSMA-11 PET/CT brings about management changes in more than 50% of prostate cancer patients with BCR (54/101; 53%). However, intended management changes early after 68Ga-PSMA-11 PET/CT frequently differ from implemented management changes.
In this prospective survey of referring physicians, we investigated whether and how 68Ga-labeled prostate-specific membrane antigen 11 (68Ga-PSMA-11) PET/CT affects the implemented management of prostate cancerpatients with biochemical recurrence (BCR). Methods: We conducted a prospective survey of physicians (NCT02940262) who referred 161 patients with prostate cancer BCR (median prostate-specific antigen value, 1.7 ng/mL; range, 0.05-202 ng/mL). Referring physicians completed one questionnaire before the scan to indicate the treatment plan without 68Ga-PSMA-11 PET/CT information (Q1; n = 101), one immediately after the scan to denote intended management changes (Q2; n = 101), and one 3-6 mo later to document the final implemented management (Q3; n = 56). The implemented management was also obtained via electronic chart review or patient contact (n = 45). Results: A complete documented management strategy (Q1 + Q2 + implemented management) was available for 101 of 161 patients (63%). Seventy-six of these (75%) had a positive 68Ga-PSMA-11 PET/CT result. The implemented management differed from the prescan intended management (Q1) in 54 of 101 patients (53%). The postscan intended management (Q2) differed from the prescan intended management (Q1) in 62 of 101 patients (61%); however, these intended changes were not implemented in 29 of 62 patients (47%). Pelvic nodal and extrapelvic metastatic disease on 68Ga-PSMA-11 PET/CT (PSMA T0N1M0 and PSMA T0N1M1 patterns) was significantly associated with implemented management changes (P = 0.001 and 0.05). Conclusion: Information from 68Ga-PSMA-11 PET/CT brings about management changes in more than 50% of prostate cancerpatients with BCR (54/101; 53%). However, intended management changes early after 68Ga-PSMA-11 PET/CT frequently differ from implemented management changes.
Authors: Wolfgang Peter Fendler; Jeremie Calais; Martin Allen-Auerbach; Christina Bluemel; Nina Eberhardt; Louise Emmett; Pawan Gupta; Markus Hartenbach; Thomas A Hope; Shozo Okamoto; Christian Helmut Pfob; Thorsten D Pöppel; Christoph Rischpler; Sarah Schwarzenböck; Vanessa Stebner; Marcus Unterrainer; Helle D Zacho; Tobias Maurer; Christian Gratzke; Alexander Crispin; Johannes Czernin; Ken Herrmann; Matthias Eiber Journal: J Nucl Med Date: 2017-04-13 Impact factor: 10.057
Authors: Jeremie Calais; Johannes Czernin; Matthias Eiber; Wolfgang P Fendler; Jeannine Gartmann; Anthony P Heaney; Andrew E Hendifar; Joseph R Pisegna; J Randolph Hecht; Edward M Wolin; Roger Slavik; Pawan Gupta; Andrew Quon; Christiaan Schiepers; Martin S Allen-Auerbach; Ken Herrmann Journal: J Nucl Med Date: 2017-05-04 Impact factor: 10.057
Authors: Simone Albisinni; Carlos Artigas; Fouad Aoun; Ibrahim Biaou; Julien Grosman; Thierry Gil; Eric Hawaux; Ksenija Limani; Francois-Xavier Otte; Alexandre Peltier; Spyridon Sideris; Nicolas Sirtaine; Patrick Flamen; Roland van Velthoven Journal: BJU Int Date: 2017-01-04 Impact factor: 5.588
Authors: Thomas A Hope; Rahul Aggarwal; Bryant Chee; Dora Tao; Kirsten L Greene; Matthew R Cooperberg; Felix Feng; Albert Chang; Charles J Ryan; Eric J Small; Peter R Carroll Journal: J Nucl Med Date: 2017-05-18 Impact factor: 10.057
Authors: Sarah M Schwarzenboeck; Isabel Rauscher; Christina Bluemel; Wolfgang P Fendler; Steven P Rowe; Martin G Pomper; Ali Afshar-Oromieh; Ken Herrmann; Matthias Eiber Journal: J Nucl Med Date: 2017-07-07 Impact factor: 10.057
Authors: Paul J Roach; Roslyn Francis; Louise Emmett; Edward Hsiao; Andrew Kneebone; George Hruby; Thomas Eade; Quoc A Nguyen; Benjamin D Thompson; Thomas Cusick; Michael McCarthy; Colin Tang; Bao Ho; Philip D Stricker; Andrew M Scott Journal: J Nucl Med Date: 2017-06-23 Impact factor: 10.057
Authors: Bruce E Hillner; Barry A Siegel; Dawei Liu; Anthony F Shields; Ilana F Gareen; Lucy Hanna; Sharon Hartson Stine; R Edward Coleman Journal: J Clin Oncol Date: 2008-03-24 Impact factor: 44.544
Authors: Isabel Rauscher; Tobias Maurer; Ambros J Beer; Frank-Philipp Graner; Bernhard Haller; Gregor Weirich; Alan Doherty; Jürgen E Gschwend; Markus Schwaiger; Matthias Eiber Journal: J Nucl Med Date: 2016-06-03 Impact factor: 10.057
Authors: Ali Afshar-Oromieh; Tim Holland-Letz; Frederik L Giesel; Clemens Kratochwil; Walter Mier; Sabine Haufe; Nils Debus; Matthias Eder; Michael Eisenhut; Martin Schäfer; Oliver Neels; Markus Hohenfellner; Klaus Kopka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-12 Impact factor: 9.236
Authors: Karine Sahakyan; Xin Li; Martin A Lodge; Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Harshad R Kulkarni; Christiane Schuchardt; Richard P Baum; Kenneth J Pienta; Martin G Pomper; Ashley E Ross; Michael A Gorin; Steven P Rowe Journal: Mol Imaging Biol Date: 2020-02 Impact factor: 3.488
Authors: Thomas A Hope; Ali Afshar-Oromieh; Matthias Eiber; Louise Emmett; Wolfgang P Fendler; Courtney Lawhn-Heath; Steven P Rowe Journal: AJR Am J Roentgenol Date: 2018-06-27 Impact factor: 3.959
Authors: Nina-Sophie Schmidt-Hegemann; Chukwuka Eze; Minglun Li; Paul Rogowski; Christian Schaefer; Christian Stief; Alexander Buchner; Constantinos Zamboglou; Wolfgang Peter Fendler; Ute Ganswindt; Clemens Cyran; Peter Bartenstein; Claus Belka; Harun Ilhan Journal: J Nucl Med Date: 2018-12-14 Impact factor: 10.057
Authors: Baowei Fei; Olayinka A Abiodun-Ojo; Akinyemi A Akintayo; Oladunni Akin-Akintayo; Funmilayo Tade; Peter T Nieh; Viraj A Master; Mehrdad Alemozaffar; Adeboye O Osunkoya; Mark M Goodman; David M Schuster Journal: J Urol Date: 2019-07-08 Impact factor: 7.450
Authors: Daniela A Ferraro; Helena I Garcia Schüler; Urs J Muehlematter; Daniel Eberli; Julian Müller; Alexander Müller; Roger Gablinger; Helmut Kranzbühler; Aurelius Omlin; Philipp A Kaufmann; Thomas Hermanns; Irene A Burger Journal: Eur J Nucl Med Mol Imaging Date: 2019-12-04 Impact factor: 9.236
Authors: Julian Müller; Daniela A Ferraro; Urs J Muehlematter; Helena I Garcia Schüler; Sarah Kedzia; Daniel Eberli; Matthias Guckenberger; Stephanie G C Kroeze; Tullio Sulser; Daniel M Schmid; Aurelius Omlin; Alexander Müller; Thomas Zilli; Hubert John; Helmut Kranzbuehler; Philipp A Kaufmann; Gustav K von Schulthess; Irene A Burger Journal: Eur J Nucl Med Mol Imaging Date: 2018-11-28 Impact factor: 9.236
Authors: Wolfgang P Fendler; Jeremie Calais; Matthias Eiber; Robert R Flavell; Ashley Mishoe; Felix Y Feng; Hao G Nguyen; Robert E Reiter; Matthew B Rettig; Shozo Okamoto; Louise Emmett; Helle D Zacho; Harun Ilhan; Axel Wetter; Christoph Rischpler; Heiko Schoder; Irene A Burger; Jeannine Gartmann; Raven Smith; Eric J Small; Roger Slavik; Peter R Carroll; Ken Herrmann; Johannes Czernin; Thomas A Hope Journal: JAMA Oncol Date: 2019-06-01 Impact factor: 31.777
Authors: Ida Sonni; Matthias Eiber; Wolfgang P Fendler; Rejah M Alano; Sitaram S Vangala; Amar U Kishan; Nicholas Nickols; Matthew B Rettig; Robert E Reiter; Johannes Czernin; Jeremie Calais Journal: J Nucl Med Date: 2020-01-10 Impact factor: 10.057
Authors: Nina-Sophie Schmidt-Hegemann; Christian Stief; Tak-Hyun Kim; Chukwuka Eze; Simon Kirste; Iosif Strouthos; Minglun Li; Wolfgang Schultze-Seemann; Harun Ilhan; Wolfgang Peter Fendler; Peter Bartenstein; Anca-Ligia Grosu; Ute Ganswindt; Claus Belka; Philipp T Meyer; Constantinos Zamboglou Journal: J Nucl Med Date: 2018-07-12 Impact factor: 10.057